Korean EGFR Registry Study for Lung Cancer Patients
Author Information
Author(s): Yeo Chang Dong, Park Dong Won, Yoon Seong Hoon, Kim Eun Young, Lee Jeong Eun, Lee Shin Yup, Choi Chang‐Min, Oh In‐Jae, Kim Do Jin, Ryu Jeong Seon, Lee Jae Cheol, Kim Young‐Chul, Jang Tae Won, Lee Kye Young, Jang Seung Hun, Kim Seung Joon, Kim Chi Young, Kim In Ae, Son Ji Woong, Lee Seung Hyeun, Park Sun Hyo, Choi Sui In, Lee Sung Yong, Jang Tae Won, Jung Chi‐Young, Kim Mi‐Hyun, Lee Hyun‐Kyung, Kang Hye Seon, Cho Hyun Jyu, Kim Seung Joon, Lee Jae Cheol, Kim Eun Young, Kim Do‐Jin, Koo So‐My, Yoon Seong Hoon, Park Chan Kwon, Ahn June Hong, Kwak Se Hyun, Yang Sei Hoon, Lee Sang Haak, Kim Jin Woo, Kim Ju Sang, Lim Jun Hyeok, Shin Song Wook, Kim Tae Hoon, Kang Da Hyun, Lee Shin Yup, Park Ji Young, Lee Chang Youl, Park Dong Won, Park Jin Han, Oh In‐Jae, Yong Suk Joong, Choi Sangbong, Um Sang‐Won
Hypothesis
The study aims to analyze clinical characteristics, treatment modalities, and outcomes in EGFR-mutated NSCLC patients.
Conclusion
The Korean EGFR Registry will provide valuable insights into the treatment outcomes of EGFR-mutated lung cancer patients in Korea.
Supporting Evidence
- EGFR mutations are common in lung cancer patients, especially in non-smokers and females.
- The study aims to provide insights into the treatment outcomes of EGFR-mutated lung cancer patients in Korea.
- Data will be collected from 40 hospitals over several years.
Takeaway
This study is like a big health check-up for lung cancer patients in Korea to see how well their treatments are working.
Methodology
The study will enroll 2000 patients from 40 hospitals and collect data on their treatment and outcomes over several years.
Limitations
The study may face challenges in patient recruitment and data collection across multiple centers.
Participant Demographics
Patients must be at least 20 years old and diagnosed with EGFR-mutated NSCLC.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website